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Gene expression profile comparison between bone metastatic and non-
metastatic prostate cancer cell lines 
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Prostate cancer is currently the most commonly diagnosed cancer and 
the second leading cancer death in man in western countries. About 90% 
of patients with advanced prostate cancer have metastases in bone 
which is currently untreatable and is the main cause of morbidity in 
these patients. It has been suggested only the so called metastasis 
initiating cells are responsible for the formation of bone metastases, via 
acquisition of a mesenchymal phenotype through epithelial to 
mesenchymal transfer (EMT). Studies have shown that P2 receptors 
were involved in prostate cancer cell growth. A recent study has 
suggested that alterations in the expression P2 of receptors were 
involved in EMT in MDA-MB-468 breast cancer cells. Similar gene 
expression alterations of P2 receptors may also present in bone 
metastasis initiating prostate cancer cells. In this study, we performed 
Taqman quantitative RT-PCR to reveal the gene expression profile of 
three human prostate cancer cell lines with different ability to form 
bone metastases, including LNCaP (non-bone metastatic to bone), C4 
2B4 (derivative of LNCaP but forming osteoblastic metastasis), and PC3 
(forming osteolytic metastasis). Total RNA was isolated from cultured 
cells using the Promega ReliaPrep RNA Cell Miniprep system. First strand 
cDNA was synthesized from 200ng RNA in a 20ʅl reaction system 
containing 250ng Promega random primer, 100mM dNTP, and 200U 
Invitrogen SuperScript III. Individual qRT-PCR was performed using equal 
amount of synthesized first strand cDNA. Results showed that RNA (CT 
value < 35) of P2X4, X5, X7, Y1, Y4, Y13, and Y14 receptors were expressed 
in all the three cell lines.  Among these P2 receptors, P2RX4 is the most 
highly expressed (CT value ~24), while P2RY14 receptor is the least 
expressed (CT value ~32). The relative gene expressions (ȴCT) were also 
compared between non-bone metastatic cell line LNCaP and bone 
metastatic cell lines C4 2B4 and PC3, using GAPDH as the endogenous 
control. Results showed that both C4 2B4 and PC3 expressed 
significantly higher level of P2XR3 but lower level or no expression of 
P2XR2, P2YR6, and P2YR11 compared to LNCaP, while the more 
mesenchymal-like PC3 cells express significantly higher levels of P2YR1 
(~8 fold) than both LNCaP and C4 2B4. In conclusion, this study has 
provided consistent and further detailed gene expression profile of 
prostate cancer cell line compared to previous studies. It also 
highlighted that alterations in gene expression of certain P2 receptor 
subtypes (P2X2, P2X3, P2Y6, and P2Y11) may be correlated with the 
ability of prostate cancer cells to metastasize to bone and a 
mesenchymal phenotype.  
